title: Distributive justice and the arrival of direct-acting antivirals: who should be first in line?
authors.affiliation: Center for Liver Disease, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medical Center, Chicago, IL 60637, USA. aaronsoh@medicine.bsd.uchicago.edu
authors.forename: Andrew
authors.initials: A
authors.lastname: Aronsohn
authors.forename: Donald
authors.initials: D
authors.lastname: Jensen
mesh_terms: D000465:Algorithms; D000998:Antiviral Agents / Q000627:therapeutic use*; D015276:Health Care Rationing / Q000941:ethics*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D009842:Oligopeptides / Q000627:therapeutic use; D011392:Proline / Q000031:analogs & derivatives / Q000627:therapeutic use; D040841:Resource Allocation / Q000941:ethics*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline